Emergent BioSolutions (EBS) Stock Forecast, Price Target & Predictions
EBS Stock Forecast
Emergent BioSolutions stock forecast is as follows: an average price target of $51.50 (represents a 443.25% upside from EBS’s last price of $9.48) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
EBS Price Target
The average price target for Emergent BioSolutions (EBS) is $51.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $65.00 to $38.00. This represents a potential 443.25% upside from EBS's last price of $9.48.
EBS Analyst Ratings
According to 3 Wall Street analysts, Emergent BioSolutions's rating consensus is 'Buy'. The analyst rating breakdown for EBS stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Emergent BioSolutions Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 04, 2022 | Wells Fargo | - | - | 14.94% | 300.84% | |
| Apr 29, 2022 | Chardan Capital | - | - | 91.29% | 585.65% |
The latest Emergent BioSolutions stock forecast, released on May 04, 2022 by Wells Fargo company, set a price target of $38.00, which represents a 14.94% increase from the stock price at the time of the forecast ($33.06), and a 300.84% increase from EBS last price ($9.48).
Emergent BioSolutions Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $9.48 | $9.48 | $9.48 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Emergent BioSolutions stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Emergent BioSolutions's last price of $9.48. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 22, 2024 | Rodman & Renshaw | Buy | Initialise | |
| Aug 16, 2024 | Benchmark | Buy | Buy | Hold |
| Aug 16, 2024 | Benchmark Co. | Underperform | Underperform | Hold |
| Jun 24, 2024 | Benchmark Co. | Underperform | Underperform | Hold |
| Jun 20, 2024 | Benchmark | Buy | Buy | Hold |
| Mar 07, 2024 | Benchmark | Positive | Buy | Upgrade |
| Apr 10, 2023 | Benchmark | Hold | Positive | Upgrade |
| Nov 10, 2022 | Benchmark | Hold | Downgrade | |
| Apr 29, 2022 | Chardan Capital | Buy | Buy | Hold |
Emergent BioSolutions's last stock rating was published by Rodman & Renshaw on Aug 22, 2024. The company Initialise its EBS rating from "null" to "Buy".
Emergent BioSolutions Financial Forecast
Emergent BioSolutions Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $270.50M | $337.90M | $165.10M | $330.70M | $240.00M | $242.70M | $307.50M | $723.20M | $329.00M | $397.50M | $343.00M | $583.00M | $385.20M | $394.70M | $192.50M | $360.30M | $311.80M | $243.20M | $190.60M | $117.81M | $116.86M |
| Avg Forecast | $279.67M | $277.60M | $275.56M | $385.60M | $248.37M | $290.33M | $190.00M | $220.25M | $293.41M | $237.43M | $216.17M | $159.73M | $297.18M | $268.30M | $270.94M | $283.57M | $669.04M | $486.84M | $398.93M | $358.41M | $573.21M | $437.89M | $294.72M | $198.89M | $357.41M | $289.27M | $212.06M | $201.16M | $863.87M | $120.93M |
| High Forecast | $279.67M | $277.60M | $275.56M | $385.60M | $248.37M | $302.50M | $190.00M | $220.25M | $293.41M | $237.43M | $216.17M | $159.73M | $297.18M | $268.30M | $270.94M | $283.57M | $669.04M | $486.84M | $398.93M | $358.41M | $573.21M | $437.89M | $294.72M | $198.89M | $357.41M | $289.27M | $212.06M | $201.16M | $1.04B | $145.12M |
| Low Forecast | $279.67M | $277.60M | $275.56M | $385.60M | $248.37M | $278.17M | $190.00M | $220.25M | $293.41M | $237.43M | $216.17M | $159.73M | $297.18M | $268.30M | $270.94M | $283.57M | $669.04M | $486.84M | $398.93M | $358.41M | $573.21M | $437.89M | $294.72M | $198.89M | $357.41M | $289.27M | $212.06M | $201.16M | $691.09M | $96.74M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 12 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.14% | 1.56% | 1.03% | 1.11% | 0.89% | 0.90% | 1.08% | 1.08% | 0.68% | 1.00% | 0.96% | 1.02% | 0.88% | 1.34% | 0.97% | 1.01% | 1.08% | 1.15% | 0.95% | 0.14% | 0.97% |
Emergent BioSolutions's average Quarter revenue forecast for Dec 23 based on 2 analysts is $293.41M, with a low forecast of $293.41M, and a high forecast of $293.41M. EBS's average Quarter revenue forecast represents a 8.47% increase compared to the company's last Quarter revenue of $270.50M (Sep 23).
Emergent BioSolutions EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 12 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-11.00M | $-292.90M | $-108.60M | $-16.10M | $-23.10M | $-30.50M | $35.30M | $305.70M | $-4.40M | $49.00M | $122.40M | $290.40M | $91.40M | $155.70M | $15.50M | $108.50M | $96.90M | $22.90M | $-1.60M | $3.18M | $25.75M |
| Avg Forecast | $16.96M | $16.83M | $16.71M | $23.38M | $15.06M | $17.60M | $11.52M | $34.76M | $17.79M | $14.40M | $13.11M | $27.48M | $18.02M | $41.62M | $42.03M | $21.72M | $103.79M | $75.53M | $61.89M | $77.59M | $88.93M | $67.93M | $45.72M | $15.50M | $55.45M | $44.88M | $32.90M | $-4.96M | $6.12M | $26.61M |
| High Forecast | $16.96M | $16.83M | $16.71M | $23.38M | $15.06M | $18.34M | $11.52M | $41.71M | $17.79M | $14.40M | $13.11M | $32.98M | $18.02M | $41.62M | $42.03M | $26.07M | $103.79M | $75.53M | $61.89M | $93.11M | $88.93M | $67.93M | $45.72M | $18.60M | $55.45M | $44.88M | $32.90M | $-3.97M | $7.35M | $31.93M |
| Low Forecast | $16.96M | $16.83M | $16.71M | $23.38M | $15.06M | $16.87M | $11.52M | $27.81M | $17.79M | $14.40M | $13.11M | $21.98M | $18.02M | $41.62M | $42.03M | $17.38M | $103.79M | $75.53M | $61.89M | $62.07M | $88.93M | $67.93M | $45.72M | $12.40M | $55.45M | $44.88M | $32.90M | $-5.95M | $4.90M | $21.29M |
| Surprise % | - | - | - | - | - | - | - | - | - | -0.76% | -22.35% | -3.95% | -0.89% | -0.55% | -0.73% | 1.63% | 2.95% | -0.06% | 0.79% | 1.58% | 3.27% | 1.35% | 3.41% | 1.00% | 1.96% | 2.16% | 0.70% | 0.32% | 0.52% | 0.97% |
1 analysts predict EBS's average Quarter EBITDA for Jun 22 to be $42.03M, with a high of $42.03M and a low of $42.03M. This is 19.08% upper than Emergent BioSolutions's previous annual EBITDA (Mar 22) of $35.30M.
Emergent BioSolutions Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 12 |
| Net Income | - | - | - | - | - | - | - | - | - | $-265.90M | $-261.30M | $-183.00M | $-88.00M | $-75.70M | $-56.40M | $-3.70M | $189.30M | $-32.70M | $4.60M | $69.70M | $185.40M | $39.50M | $92.70M | $-12.50M | $46.90M | $43.20M | $-9.50M | $-26.00M | $-4.91M | $10.48M |
| Avg Forecast | $2.22M | $71.72M | $7.78M | $83.40M | $-22.80M | $5.75M | $-63.11M | $-3.64M | $-10.56M | $-12.42M | $-35.95M | $-2.88M | $197.01M | $-3.24M | $19.99M | $-2.28M | $222.65M | $123.52M | $76.27M | $44.18M | $167.64M | $111.25M | $35.94M | $-12.50M | $91.22M | $47.11M | $8.79M | $-80.60M | $-9.44M | $10.83M |
| High Forecast | $2.22M | $71.72M | $7.78M | $83.40M | $-22.80M | $5.75M | $-63.11M | $-2.91M | $-10.56M | $-12.42M | $-35.95M | $-2.30M | $236.42M | $-3.24M | $19.99M | $-1.82M | $222.65M | $123.52M | $76.27M | $53.02M | $167.64M | $111.25M | $35.94M | $-10.00M | $91.22M | $47.11M | $8.79M | $-64.48M | $-7.55M | $13.00M |
| Low Forecast | $2.22M | $71.72M | $7.78M | $83.40M | $-22.80M | $5.75M | $-63.11M | $-4.37M | $-10.56M | $-12.42M | $-35.95M | $-3.46M | $157.61M | $-3.24M | $19.99M | $-2.73M | $222.65M | $123.52M | $76.27M | $35.35M | $167.64M | $111.25M | $35.94M | $-15.00M | $91.22M | $47.11M | $8.79M | $-96.72M | $-11.32M | $8.67M |
| Surprise % | - | - | - | - | - | - | - | - | - | 21.41% | 7.27% | 63.53% | -0.45% | 23.34% | -2.82% | 1.63% | 0.85% | -0.26% | 0.06% | 1.58% | 1.11% | 0.36% | 2.58% | 1.00% | 0.51% | 0.92% | -1.08% | 0.32% | 0.52% | 0.97% |
Emergent BioSolutions's average Quarter net income forecast for Mar 22 is $-2.28M, with a range of $-2.73M to $-1.82M. EBS's average Quarter net income forecast represents a -101.20% decrease compared to the company's last Quarter net income of $189.30M (Dec 21).
Emergent BioSolutions SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 12 |
| SG&A | - | - | - | - | - | - | - | - | - | $86.00M | $91.40M | $100.50M | $94.20M | $80.20M | $81.10M | $84.80M | $94.20M | $82.10M | $91.20M | $80.90M | $82.10M | $75.50M | $76.00M | $69.70M | $72.20M | $65.00M | $70.80M | $65.40M | $40.20M | $35.15M |
| Avg Forecast | $72.23M | $71.69M | $71.17M | $99.59M | $64.14M | $74.98M | $49.07M | $83.51M | $75.78M | $61.32M | $55.83M | $66.01M | $98.04M | $68.69M | $69.37M | $52.18M | $171.30M | $124.65M | $102.14M | $51.28M | $146.76M | $112.11M | $75.46M | $69.70M | $91.51M | $74.06M | $54.29M | $51.50M | $77.30M | $36.32M |
| High Forecast | $72.23M | $71.69M | $71.17M | $99.59M | $64.14M | $78.12M | $49.07M | $100.21M | $75.78M | $61.32M | $55.83M | $79.22M | $117.65M | $68.69M | $69.37M | $62.62M | $171.30M | $124.65M | $102.14M | $61.54M | $146.76M | $112.11M | $75.46M | $83.64M | $91.51M | $74.06M | $54.29M | $51.50M | $92.76M | $43.59M |
| Low Forecast | $72.23M | $71.69M | $71.17M | $99.59M | $64.14M | $71.84M | $49.07M | $66.81M | $75.78M | $61.32M | $55.83M | $52.81M | $78.43M | $68.69M | $69.37M | $41.75M | $171.30M | $124.65M | $102.14M | $41.03M | $146.76M | $112.11M | $75.46M | $55.76M | $91.51M | $74.06M | $54.29M | $51.50M | $61.84M | $29.06M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.40% | 1.64% | 1.52% | 0.96% | 1.17% | 1.17% | 1.63% | 0.55% | 0.66% | 0.89% | 1.58% | 0.56% | 0.67% | 1.01% | 1.00% | 0.79% | 0.88% | 1.30% | 1.27% | 0.52% | 0.97% |
Emergent BioSolutions's average Quarter SG&A projection for Dec 23 is $75.78M, based on 2 Wall Street analysts, with a range of $75.78M to $75.78M. The forecast indicates a -11.89% fall compared to EBS last annual SG&A of $86.00M (Sep 23).
Emergent BioSolutions EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 12 |
| EPS | - | - | - | - | - | - | - | - | - | $-5.13 | $-5.15 | $-3.65 | $-1.76 | $-1.52 | $-1.13 | $-0.07 | $3.54 | $-0.61 | $0.09 | $1.31 | $3.51 | $0.75 | $1.76 | $-0.24 | $0.91 | $0.84 | $-0.18 | $-0.51 | $-0.10 | $0.26 |
| Avg Forecast | $0.04 | $1.29 | $0.14 | $1.50 | $-0.41 | $0.10 | $-1.14 | $-0.98 | $-0.19 | $-0.22 | $-0.65 | $-1.29 | $0.04 | $-0.06 | $0.38 | $0.13 | $4.23 | $2.35 | $1.45 | $1.15 | $3.19 | $2.12 | $0.68 | $0.01 | $1.73 | $0.90 | $0.17 | $0.09 | $0.42 | $0.31 |
| High Forecast | $0.04 | $1.29 | $0.14 | $1.50 | $-0.41 | $0.10 | $-1.14 | $-0.98 | $-0.19 | $-0.22 | $-0.65 | $-1.29 | $0.04 | $-0.06 | $0.38 | $0.13 | $4.23 | $2.35 | $1.45 | $1.15 | $3.19 | $2.12 | $0.68 | $0.01 | $1.73 | $0.90 | $0.17 | $0.09 | $0.51 | $0.37 |
| Low Forecast | $0.04 | $1.29 | $0.14 | $1.50 | $-0.41 | $0.10 | $-1.14 | $-0.98 | $-0.19 | $-0.22 | $-0.65 | $-1.29 | $0.04 | $-0.06 | $0.38 | $0.13 | $4.23 | $2.35 | $1.45 | $1.15 | $3.19 | $2.12 | $0.68 | $0.01 | $1.73 | $0.90 | $0.17 | $0.09 | $0.34 | $0.25 |
| Surprise % | - | - | - | - | - | - | - | - | - | 22.97% | 7.96% | 2.82% | -40.00% | 24.65% | -2.97% | -0.58% | 0.84% | -0.26% | 0.06% | 1.14% | 1.10% | 0.35% | 2.58% | -24.00% | 0.52% | 0.94% | -1.08% | -5.41% | -0.24% | 0.84% |
According to 1 Wall Street analysts, Emergent BioSolutions's projected average Quarter EPS for Mar 22 is $0.13, with a low estimate of $0.13 and a high estimate of $0.13. This represents a -96.47% decrease compared to EBS previous annual EPS of $3.54 (Dec 21).
Emergent BioSolutions Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EBS | Emergent BioSolutions | - | - | 443.25% | Buy |
| COLL | Collegium Pharmaceutical | - | - | 35.18% | Buy |
| ZTS | Zoetis | - | - | 28.68% | Buy |
| ALKS | Alkermes | - | - | 26.41% | Hold |
| BHC | Bausch Health Companies | - | - | 25.47% | Hold |
| NBIX | Neurocrine Biosciences | - | - | 17.27% | Buy |
| ITCI | Intra-Cellular Therapies | - | - | 10.28% | Buy |
| PBH | Prestige Consumer Healthcare | - | - | 5.48% | Buy |
| DCPH | Deciphera Pharmaceuticals | - | - | 2.85% | Hold |
| PETQ | PetIQ | - | - | 0.06% | Buy |
| LFCR | Lifecore Biomedical | - | - | -11.08% | Buy |